African Journal of Biotechnology Vol. 5 (25), pp. 2503-2509, 29 December 2006   

ISSN 1684–5315 © 2006 Academic Journals        

Review

Therapeutic implications of recombinant human erythropoietin in anaemic related clinical manifestations

D. Annieruth Helena, A. Jyothsna, N. Lakshmi, P. Jaganmohana Rao, G. Venkateswara Rao* and K.R.S. Sambasiva Rao

Centre for Biotechnology, Acharya Nagarjuna University Nagarjunanagar – 522 510, Guntur, A.P India.

*Corresponding author. E-mail: krssrao@yahoo.com.

Accepted 23 November, 2006

The introduction of recombinant human erythropoietin (RHUEPO) has revolutionised the treatment strategies for patients suffering with anaemia of chronic renal disease and chronic heart failure. Clinical studies and several observational evidences have demonstrated that RHUEPO is also useful in various non-uraemic conditions including haematological and oncological disorders, prematurity, HIV infection and preoperative therapies. The successful treatment of all the anaemic related malfunctions with recombinant human erythropoietin (RHUEPO) has become a standard treatment tool for dialysis pat-ients and as an interesting therapeutic option for several forms of non-renal anaemia. As a cones-quence of both, RHUEPO has achieved the highest annual sales worldwide and the potential of it increases its scope in the future prospective also.

Key words: Recombinant human erythropoietin, anaemia, recombinant human erythropoietin therapy, erythropoietin-mediated malfunctions.